Global Zolbetuximab Market Strategic Research Report

Scope of the Report

The global Zolbetuximab market size is predicted to grow from US$ 411 million in 2025 to US$ 2,569 million in 2032; it is expected to grow at a CAGR of 18.5% from 2026 to 2032.

Zolbetuximab is a recombinant, chimeric monoclonal antibody directed against Claudin 18.2 (CLDN18.2), a tight junction protein specifically overexpressed in certain gastrointestinal malignancies. It binds selectively to CLDN18.2 on tumor cell surfaces, triggering antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to induce tumor cell lysis and inhibit tumor progression. Designed for targeted therapy of CLDN18.2-positive advanced solid tumors, it serves as a key targeted agent for gastric and gastroesophageal junction cancers, offering a new treatment option for patients with limited therapeutic choices.In 2025, global Zolbetuximab production reached approximately 410,000–420,000 vials

Zolbetuximab, as the world’s first and only approved monoclonal antibody targeting Claudin 18.2 (CLDN18.2), has established a core market position in the precision treatment of gastric and gastroesophageal junction adenocarcinomas due to its pioneering status. Its commercial value relies on the unique high expression specificity of this target in certain gastrointestinal malignancies and the significant efficacy advantages demonstrated in key clinical trials, opening up a new field for patients with limited responses to traditional treatment regimens. The current market is dominated by the original developer with no direct competing products, allowing it to rapidly set treatment standards and build brand barriers after approval in major global markets. The core driver of market growth stems from the substantial unmet medical need in advanced gastric cancer, as well as the popularization of companion diagnostic technologies and improved patient screening rates. Although high pricing has restricted market accessibility to a certain extent, its market outlook remains broad as a breakthrough therapy. In the future, its market lifecycle will depend on the continuous expansion of indications, deeper penetration into global markets, progress in medical insurance access, and response to the increasingly competitive environment brought by the launch of subsequent drugs targeting the same target, including monoclonal antibodies, ADCs and cell therapies.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Zolbetuximab market?

What factors are driving Zolbetuximab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Zolbetuximab market opportunities vary by end market size?

How does Zolbetuximab break out by Type, by Application?

This report presents a comprehensive overview of the global Zolbetuximab market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 100 mg / bottle
• 300 mg / bottle

Segment by Dosage Form

• Lyophilized Powder for Injection
• 2 Class Two Zolbetuximab 静脉输注用制剂 3 Class Three Zolbetuximab 4 Class Four Zolbetuximab 5 Class Five Zolbetuximab 6 Class Six Zolbetuximab 7 Class Seven Zolbetuximab 8 Class Eight Zolbetuximab 9 Class Nine Zolbetuximab 10 Class Ten Zolbetuximab

Segment by Route of Administration

• Intravenous Infusion
• Intravenous Injection

Segment by Combination Therapy

• Combination With Immunotherapy
• Combination With Anti-Angiogenic Agents

Segment by Application

• Gastric Cancer
• Gastroesophageal Junction Cancer
• Advanced Gastrointestinal Malignancies
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Zolbetuximab market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Gastric Cancer, Gastroesophageal Junction Cancer, Advanced Gastrointestinal Malignancies evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact